PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma

BACKGROUND: Sarcomas represent 10%–15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumor types, but data in advanced sarcomas, particularly withi...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheinberg, Tahlia, Lomax, Anna, Tattersall, Martin, Thomas, David, McCowage, Geoff, Sullivan, Michael, Karim, Rooshdiya, Luk, Peter P., Mahar, Annabelle, Bonar, Fiona, Bhadri, Vivek A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451371/
https://www.ncbi.nlm.nih.gov/pubmed/33314769
http://dx.doi.org/10.1002/cnr2.1327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451371/
https://www.ncbi.nlm.nih.gov/pubmed/33314769
http://dx.doi.org/10.1002/cnr2.1327

Ejemplares similares